Background Image
Table of Contents Table of Contents
Previous Page  596 / 1498 Next Page
Information
Show Menu
Previous Page 596 / 1498 Next Page
Page Background

indolent lymphoma: an open-label, phase 2 trial

Fowler et al

Lancet Oncol. 2014 Nov;15(12):15.

Can cytotoxic chemotherapy be avoided ?

Lenalidomide 20mg Days 1-21 Cycles 1-6*

Months

1 2 3 4 5 6

Rituximab 375mg/M

2

Day 1 of Cycles 1-6

If clinical benefit, can

proceed to 12 cycles

Planned Enrollment

N= 50 Follicular lymphoma (grade I/II)

N=30 Small lymphocytic lymphoma

N=30 Marginal zone lymphoma

R= RESTAGING

R

Lenalidomide 20mg Days 1-21 Cycles 7-12*

Rituximab 375mg/M

2

Day 1 of Cycles 7-12

R

R

R

7 8 9 10 11 12

*SLL patients: Dose escalation of lenalidomide

starting with cycle 1: (10mg, 15mg, 20mg)